Daily Mosnodenvir as Dengue Prophylaxis in a Controlled Human Infection Model.

ABSTRACT:

Background

Approximately half the worldwide population is at risk for dengue. No antiviral prophylaxis or treatment options are available.

Methods

In a phase 2a, double-blind, randomized trial, we assigned healthy adults to receive oral mosnodenvir once daily as a low dose (40-mg loading dose followed by 10-mg maintenance dose), medium dose (200 mg followed by 50 mg), or high dose (600 mg followed by 200 mg) or matched placebo. Loading doses were given for 5 days and maintenance doses for 21 days. In a controlled human infection model, participants received subcutaneous inoculation of an underattenuated dengue virus serotype 3 (DENV-3) strain (rDEN3Δ30) on the day of the first maintenance dose (day 1). The primary efficacy end point was the DENV-3 RNA load, assessed as the l

SUBMITTER: Durbin AP 

PROVIDER: S-EPMC12662413 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature